VEGFA vs VEGFR2: Ligand and Receptor in Tumour Angiogenesis

The VEGF Family

The VEGF family includes VEGFA, VEGFB, VEGFC, VEGFD and placental growth factor, acting through three receptors, VEGFR1, VEGFR2 and VEGFR3. VEGFA is the dominant driver of new blood-vessel growth; VEGFC and VEGFD act mainly on lymphatic vessels through VEGFR3.

VEGFA itself exists in several splice forms that differ in how tightly they bind the extracellular matrix versus diffusing freely, shaping the gradient that guides vessel sprouting.

VEGFR2: The Main Signalling Receptor

VEGFR2 (also called KDR) is a receptor tyrosine kinase on endothelial cells. VEGFA binding causes receptor dimerisation and autophosphorylation, activating pathways that drive endothelial proliferation, migration, survival and increased vascular permeability.

VEGFR1 binds VEGFA with higher affinity but weak kinase activity and is thought to act partly as a decoy that tunes how much VEGFA reaches VEGFR2.

What Turns VEGFA On in Tumours

Hypoxia is the classic trigger: HIF transcription factors directly increase VEGFA expression when oxygen is low. Oncogenic signalling through RAS, PI3K and others, along with inflammatory cytokines, also raises VEGFA.

The result is the angiogenic switch, where a growing tumour tips from dormant to vascularised.

Drugs Targeting Each Side

Ligand-side agents include the anti-VEGFA antibody bevacizumab and the decoy receptor aflibercept, which mop up circulating VEGF. Receptor-side agents include the anti-VEGFR2 antibody ramucirumab and many small-molecule tyrosine-kinase inhibitors (sunitinib, sorafenib, lenvatinib, cabozantinib and others) that block VEGFR2 and usually several related kinases.

Benefit varies widely by tumour type, and these drugs are generally used in combination or in specific settings rather than universally.

Interpretation Notes

There is no established, widely used predictive biomarker for anti-VEGF therapy; circulating VEGF levels and tumour microvessel density have not proven reliable for treatment selection.

A report mentioning VEGFA expression or amplification describes tumour biology and should not be read as a direct treatment recommendation.

Key Takeaways

• ·VEGFA is the main pro-angiogenic ligand; VEGFR2 carries most of the signal.
• ·Hypoxia (via HIF) and oncogenic signalling raise tumour VEGFA.
• ·Drugs target the ligand (bevacizumab, aflibercept) or the receptor (ramucirumab, TKIs).
• ·No reliable predictive biomarker for anti-VEGF therapy is in routine use.